Disclosed is a method of treatment using a topical composition including essential sombination of synergistically acting phyto-active materials, non-psychotropic phtocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarian Cannabigerol in combination with extract of Calendula flower and the formulation of the base to ensure the features of anti-inflammation, anti-oxidation, emollient, and bactericidal components. The topical composition is an emollient dedicated for reduction of skin lesions caused by atopic dermatitis, urticaria, radiotherapy and UV induced skin damage and acne. In addition, the topical composition could reduce secretion of fats, facilitate deep skin hydration, reduce pores, and exert soothing effects.

A composition comprising an oat derived, salt precipitated β-(1,3)-(1,4) glucan having a molecular weight from about 150 kDa to about 250 kDa, a Mw/Mn ratio of about 1.0 to about 1.25, and a D3/D4 ratio of about 1.5 to less than about 2.0.

A hand-operated screw press for users to press cannabis flower or isolated trichome heads without an air compressor, hydraulic unit or solvents used in the process. A digital load cell is provided, as is a full color LCD touch screen display for showing and recording force in real time. A mechanism for detecting the end point of a process is also provided. A recipe representative of heat plate temperature, time of operation, pressure ramping, capacity of the screw press, type of raw material, or mass of raw material can be created and stored for use on any suitable rosin press machine.

The present invention relates to a novel black garlic extract using garlic bulbs separated into six bulbs as a raw material instead of conventional whole garlic and a preparation method thereof. There is an excellent effect of providing a novel black garlic extract with various functionalities of high sweetness and high viscosity and improved flavor and reddish brown color as well as induce high-concentration conversion of 10 times or more to a S-allyl-cysteine compound in which a functional ingredient of raw garlic having antioxidation, reduction in blood cholesterol, improved liver function, and enhanced blood pressure is present in a small amount of 10 ppm or less by maximizing conversion of starch into reducing sugar for most preferably 15 days in a 90% to 100% saturated steam state and a liquefied enzymatic action temperature of 75° C. to 80° C. or lower without separate enzyme addition, and optimizing the action of proteases.

The present invention relates to a composition for preventing sleep disorders or insomnia, containing an enzyme-treated Ashwagandha extract as an active ingredient, and specifically, since it was confirmed that in an animal model and a sleep disorder animal model, which were administered an enzyme-treated Ashwagandha extract, sleep latency and awake time during sleep were decreased, sleep time, non-rapid eye movement (NREM) sleep time and δ-waves were increased, and as a result, sleep activity was improved, the enzyme-treated Ashwagandha extract can be used as an active ingredient of a composition for preventing or treating sleep disorders or insomnia.

A method for extracting bioactive compounds from plant materials using supercritical glycerin and at least one inert co-solvent that lowers the effective supercritical point of the supercritical glycerin to its boiling point, and the extracts obtained from the method.

A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin or digoxin is used to treat the viral infection or the disease state of said viral infection.

Disclosed is a composition for suppression of avian viral epidemic diseases, including horseradish extract and cinnamon extract. According to the disclosure, a mixed composition of extracts from natural products, and a bactericidal disinfectant composition including the mixed composition are provided to prevent and combat viral diseases damaging bird farms.

The present invention discloses a method for producing cannabis products comprising steps of providing preselected plant parts or whole plant; optionally drying, grinding and/or extracting the plant to provide a first extract; obtaining a pharmaceutical product performing the following cyclic algorithm during or after the previous step: heating the plant/extract to specific temperature range, and collecting vaporized and/or particularized material into fractions; separating the fractions into sub-fractions characterized by particle size; rendering the separated material into a storable intermediate comprising sub-fractions characterized by particle size sufficient to passively cross the BBB; formulating the storable intermediate suitable for administration; wherein at least one of the steps of separating and rendering in the form of a storable intermediate comprise steps of reducing the volume of the collected material; further wherein the steps of reducing the volume comprise steps of water capture of water-soluble particles, and optionally of cycling through a filter membrane.

A method for producing cannabinoid-containing crystals includes providing a CBGA-containing plant material that includes at least 2% CBGA by dry weight. The CBGA-containing plant material is exposed to a fluid in a supercritical state to extract components of the CBGA-containing plant material. A fraction of the extracted components is coalesced. The coalesced fraction of the extracted components includes cannabinoid-containing crystals containing at least one of CBGA and a cannabinoid derivative of CBGA from the carbon dioxide.